ESC 365 - Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

ESC Premium Access

Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Session: GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?

Topic: Diabetes, dysglycaemia and metabolic syndrome

Speaker: Professor L. Ryden (Stockholm, SE)

Sponsored by Novo Nordisk

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

37 presentations

1 follower

3 more presentations in this session

Results from the LEADER cardiovascular outcomes trial.

Speaker: Doctor M. Husain (Toronto, CA)

Translating trials into practice – Clinical implications .

Speaker: Professor M. Pfeffer (Boston, US)

Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Speaker: Professor L. Ryden (Stockholm, SE) Doctor M. Husain (Toronto, CA) Professor M. Pfeffer (Boston, US)

Access the full session

GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?

Speakers: Professor L. Ryden, Doctor M. Husain, Professor M. Pfeffer, Professor L. Ryden, Doctor M. Husain...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources